An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain

Birmingham

Hoover

Mobile

Mesa

Phoenix

Tempe

Tucson

Jonesboro

Little Rock

Anaheim

Carmichael

Encinitas

Fresno

Huntington Park

Laguna Hills

Los Gatos

Pico Rivera

Pismo Beach

Sacramento

San Diego

Upland

Westlake Village

Stamford

Trumbull

Chiefland

Clearwater

Fort Myers

Hallandale

Hollywood

Jacksonville

Kissimmee

Miami

New Port Richey

Oldsmar

Pembroke Pines

Plantation

Port Orange

Sarasota

Tamarac

Tampa

Athens

Augusta

Decatur

Marietta

Perry

Suwanee

Woodstock

Honolulu

Boise

Meridian

Chicago

Avon

Evansville

Indianapolis

Valparaiso

West Des Moines

Overland Park

Prairie Village

Topeka

Madisonville

Baton Rouge

Lake Charles

Mandeville

Metairie

New Orleans

Columbia

Owings Mills

Rockville

Boston

Brighton

Fall River

North Dartmouth

Wellesley Hills

West Yarmouth

East Lansing

Grand Blanc

Kalamazoo

Troy

St Louis

Omaha

Cherry Hill

Albuquerque

Mamaroneck

New York

Williamsville

Greensboro

Raleigh

Winston-Salem

Cincinnati

Kettering

Toledo

Oklahoma City

Medford

Allentown

Chester

Duncansville

Morrisville

Philadelphia

Greenville

Prosperity

Sioux Falls

Clarksville

Nashville

Amarillo

Austin

Dallas

Houston

Hurst

Lubbock

Odessa

San Antonio

Salt Lake City

Danville

Roanoke

Virginia Beach

Bellevue

Tacoma

Milwaukee

Adelaide

Melbourne

Newcastle

Woodville North

Chilliwack

Kelowna

Penticton

Vancouver

St. John's

Ajax

Brampton

Greater Sudbury

Kitchener

London

Markham

Mississauga

Ottawa

Sarnia

Toronto

Vancouver

Charlottetown

Montreal

Pointe-Claire

Saint Romuald

Sherbrooke

Saskatoon

Halifax

Christchurch

Tauranga

Wellington